Intraocular Pressure Elevation after Injection of Triamcinolone Acetonide: A Multicenter Retrospective Case-Control Study - 20/08/11
, Keiichiro Iwao a, Takahiro Kawaji a, Yoshio Hirano b, Yuichiro Ogura b, Kazuyuki Hirooka c, Fumio Shiraga c, Yoriko Nakanishi d, Hiroyuki Yamamoto d, Akira Negi d, Yuka Shimonagano e, Taiji Sakamoto e, Chieko Shima f, Miyo Matsumura f, Hidenobu Tanihara a
Inquiries to Masaru Inatani, Department of Ophthalmology and Visual Science, Kumamoto University Graduate School of Medical Sciences, 1-1-1, Honjo, 860-8556 Kumamoto, JapanRésumé |
Purpose |
To determine the risk factors for intraocular pressure (IOP) elevation after the injection of triamcinolone acetonide (TA).
Design |
Retrospective interventional case-control study.
Methods |
setting: Multicenter. patient population: Four hundred and twenty-seven patients. observation procedures: Intraocular pressure levels after TA treatment by the sub-Tenon capsule injection (STI; 12 mg, 20 mg, or 40 mg), intravitreal injection (IVI; 4 mg or 8 mg), or the combination of STI (20 mg) and IVI (4 mg), and IOP levels after two TA treatments. main outcome measure: Risk factors for IOP levels of 24 mm Hg or higher.
Results |
Younger age (hazards ratio [HR], 0.96/year; P < .0001), IVI (HR, 1.89/year; P < .0001), and higher baseline IOP (HR, 1.15/mm Hg; P = .003) were identified as risk factors. Dose dependency was shown in STI-treated eyes (HR, 1.07/mg; P = .0006), as well as after IVI (HR, 1.64/mg; P = .013). The combination of STI and IVI was a significant risk factor (HR, 2.27; P = .003) compared with STI alone. In eyes receiving two TA treatments, IVI (HR, 2.60; P = .010), higher IOP elevation after the first injection (HR, 1.18/mm Hg; P = .011), and increased dosage of STI (HR, 1.07/mm Hg; P = .033) were risk factors.
Conclusions |
Younger age, higher baseline IOP, IVI, and increased TA dosage were associated with TA-induced IOP elevation. IOP elevation after repeated TA injection was frequently associated with eyes treated with IVI, high IOP elevation after the first injection, and high doses of STI.
Le texte complet de cet article est disponible en PDF.Plan
Vol 145 - N° 4
P. 676 - avril 2008 Retour au numéro
Article précédent
- Reimplantation of a Fluocinolone Acetonide Sustained Drug Delivery Implant for Chronic Uveitis
- Glenn J. Jaffe
- Vitreous Penetration of Orally Administered Valacyclovir
- Tony H. Huynh, Mark W. Johnson, Grant M. Comer, Douglas N. Fish
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?